An important piece of information from our study is the synergistic effect of combining mTOR/PI3K inhibitors with MEK1/2 blockades, especially in NRAS-mutated melanoma, where reciprocal activation limits the efficacy of monotherapy. The gene discussed is NRAS; the disease is melanoma.